Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.
An experimental obesity pill from Arena Pharmaceuticals won the support of U.S. advisers on Thursday, as public health advocates push for new solutions to the nation's growing obesity epidemic.
The "Mad Money" host learns more about this biotechnology company, which he thinks is a great speculative stock.
Few stock sectors are as reliable as drugs and health care, and astute investors know that companies such as Merck, Pfizer, and Abbott Laboratories have delivered healthy returns over the years. One stock that investors have become less enamored with, however, is Johnson & Johnson.
Many jobs that let reserved types work in solitude offer poor salaries and unchallenging work. But there are other careers that are stimulating, well-paying and require little human contact.
The makers of a deer antler velvet product are suing Major League Baseball for libel after the league told players to stop taking the performance enhancer so as not to risk testing positive for a steroid that wasn't listed as an ingredient.
The “Mad Money” host offers his earnings expectations for Time Warner, CVS Caremark, Garmin, Allergan and Clorox.
The largest U.S. drugmaker said its net income fell in the latest period as sales declined after the company lost its exclusivity on the cholesterol drug Lipitor at the end of November.
The "Mad Money" host shares his earnings expectations for Biogen Idec, Cummins, Emerson Electric and Chesapeake Energy.
Merck said Friday that its first-quarter profit jumped 67 percent despite lower-than-expected sales, due to lower spending on production, marketing and research as well as an arbitration charge a year ago.
The "Mad Money" host shares his earnings expectations for International Paper, Procter & Gamble and V.F. Corp.
The "Mad Money" host reveals his earnings expectations for Celgene, Exxon-Mobil, Amazon.com, Deckers Outdoor and Zynga.
John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.
Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.
Amylin Pharmaceuticals, which spurned a $3.5 billion takeover bid from Bristol-Myers Squibb and is fending off a lawsuit from activist investor Carl Icahn, started reaching out to potential buyers last week, sources familiar with the situation said on Sunday.
A two-person surgical team has created a new, inexpensive bone-grafting device without having to go to big pharma.
Based on my discussions with several analysts, from reading their reports, I suspect that the earnings revisions occurred after the analysts had conversations with Mylan.
In 2011, Mylan’s longtime chief executive Robert Coury, who gave up the post at the end of the year to become executive chairman (he’s also chairman of the board) earned cash compensation of $7.4 million.
Investors can expect a muted first-quarter earnings season, and should add pharmaceutical stocks to their portfolios to guard against potentially rocky times ahead, according to investment bank UBS.
Shareholders of all girth face a host of meetings with the pharmaceutical company currently in the crosshairs of a hostile bid from Swiss drug maker Roche.